Key population-led services now account for the majority of Thai PrEP users
The ethics of phylogenetics? Central issues surrounding the use of molecular HIV surveillance
Community-led monitoring of HIV services leads to investment and policy change
Zambian patients on dolutegravir and recycled tenofovir regimens have high risk of TB even after switch
Giving antibodies to prevent vertical transmission in Africa would be cost-effective or even save money, study finds
Community organisations have formed the backbone of the HIV response in Ukraine
Long-term Canadian study shows HIV-exposed children have worse health outcomes
Long-acting cabotegravir and rilpivirine may be feasible for people without viral suppression
A cure must be a cure for all: why more HIV cure research in Africa is needed
Social support can buffer the effects of stigma on suicidality among young people living with HIV
Package of person-centred care improves viral suppression for young people living with HIV in Kenya and Uganda
The challenges integrating U=U into HIV care around the world
Rate of neural tube defects is no higher on dolutegravir
We still have no HIV cure. But we have a better strategy for finding one
Broader hepatitis C treatment not leading to more reinfections in people with HIV
Injectable PrEP is just as effective for transgender women as it is for gay men, study analysis finds
New formulations and alternative injection sites might allow self-administration of long-acting cabotegravir and rilpivirine
Early response to Ukrainian refugees enabled continuity of HIV care, but longer-term issues must be addressed as war drags on
